Type 2 diabetes is a growing health crisis in India, with the recent International Diabetes Federation (IDF) 2025 atlas showing that India accounted for 90 million diabetics in 2024. At Zydus Healthcare Ltd., we are committed to pioneering innovative solutions to combat this burden. Driven by this mission, Imeglyn—our breakthrough therapy for T2DM—is setting a new benchmark in diabetes management with India’s largest real-world study to date.

A Record-Breaking Milestone

Our IndiTimes Study Dissemination Campaign has been a landmark initiative in diabetes care. Through an in—clinic digital study reading activity with over 12,000 healthcare professionals participants, Zydus has earned a coveted place in the Asia Book of Records—a testament to the campaign’s scale, impact, and scientific rigour.

IMEGLYN, targeting the mitochondrial bioenergetics, tackles one of the root causes of T2DM: mitochondrial dysfunction and plays a crucial role in maintaining glucose homeostasis. Its triple mechanism of action—enhancing beta cell function and insulin secretion, improving insulin sensitivity, and reducing hepatic gluconeogenesis—makes it a truly transformative solution in the fight against diabetes.

Key Findings from the IndiTimes Study: Significant Glycemic Control

• Mean HbA1c Reduction: 1.12%
• Mean Fasting Plasma Glucose (FPG) Reduction: 29.41 mg/dl
• Mean Postprandial Glucose (PPG) Reduction: 62.41 mg/dl

Powering Better Outcomes

With a strong foundation in science and real-world outcomes, Imeglyn continues to redefine standards of care. It’s not just a medication—it’s a movement toward better health for people living with diabetes.